Lirafugratinib treats bile duct cancer with FGFR2 changes, but its label lists no FDA-authorized test. Learn what patients need for testing and eye checks.
Patients with Bile Duct Cancer Need FGFR2 Testing Before Lirafugratinib, but the Label Lists No FDA-Authorized Companion Test
by | Oct 19, 2026 | Uncategorized | 0 comments
Recent Comments